Transversalis Fascia Plane BlockNCT07033104
Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section
A study testing us guided Transversalis fascia plane block in people with Transversalis Fascia Plane Block, run by Tanta University at 1 site in Egypt.
Trial summary
Evaluate calcitonin as an adjuvant to bupivacaine in ultrasound guided tansversalis fascia plane block Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Transversalis Fascia Plane Block
- What is being tested?
- us guided Transversalis fascia plane block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2025to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- female pt ASA2 scheduled for cs under spinal anesthesia
Who cannot join
- patient refusal ASAmore than 3 patients with pregnancy related disease emergency cs history of coagulopathy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
tanta University hospital
Tanta, Gharbia Governorate
marwa ahmed Abogabal, PhD, +201004190210, dr_mora1985@med.tanta.edu.eg
About this study
Official title: Analgesic Effect of Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section, A Prospective Randomized Study
Evaluate calcitonin as an adjuvant to bupivacaine in ultrasound guided tansversalis fascia plane block
- Conditions
- Transversalis Fascia Plane Block
- Being tested
- us guided Transversalis fascia plane block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
us guided Transversalis fascia plane blockOther
addition of calcitonin to pubivacaine
| Study group | Role | What they receive |
|---|---|---|
| Transversalis fascia plane block with bupivacaine | Active comparator | us guided transversalis fascia plane block with bupivacaine Receives: Other: us guided Transversalis fascia plane block |
| Transversalis fascia plane block with calcitonin and bupivacaine | Active comparator | us guided transvesalis fascia plane block with calcitonin and bupivacaine Receives: Other: us guided Transversalis fascia plane block |
What is being measured
The primary outcome is the main question the study is designed to answer.
time to first rescue analgesia
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2025
- Study start1 Apr 2025
- Primary completion1 Aug 2025 (estimated)
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transversalis Fascia Plane BlockStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Ahmed Abogabal, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07033104
- Sponsor's protocol ID
- 36264PR1160
- Status last verified
- May 2025
- First submitted
- 13 Jun 2025
- Last updated
- 24 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analgesic Effect of Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section, A Prospective Randomized Study
- ClinicalTrials.gov ID
- NCT07033104
- Acronym / sponsor ID
- 36264PR1160
- Conditions
- Transversalis Fascia Plane Block
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Aug 2025 (estimated)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 24 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluate calcitonin as an adjuvant to bupivacaine in ultrasound guided tansversalis fascia plane block
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transversalis fascia plane block with bupivacaine | Active comparator | Other: us guided Transversalis fascia plane blockus guided transversalis fascia plane block with bupivacaine |
| Transversalis fascia plane block with calcitonin and bupivacaine | Active comparator | Other: us guided Transversalis fascia plane blockus guided transvesalis fascia plane block with calcitonin and bupivacaine |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- female pt ASA2 scheduled for cs under spinal anesthesia
Key exclusion criteria (1 listed)
- patient refusal ASAmore than 3 patients with pregnancy related disease emergency cs history of coagulopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| us guided Transversalis fascia plane blockaddition of calcitonin to pubivacaine | Other | Transversalis fascia plane block with bupivacaine, Transversalis fascia plane block with calcitonin and bupivacaine |
Primary outcome
time to first rescue analgesia
Time frame: 24 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2025.
Related trials for Transversalis Fascia Plane Block
Not yet recruiting
PQLB vs TFPB in HALDN
Analgesia, Donor Nephrectomy
Not yet recruitingObservational study
Comparison of Quadro-Iliac Plane Block and Transversalis Fascia Plane Block for Open Inguinal Hernia Repair
Inguinal Hernia Unilateral
Recruiting
Intrathecal Morphine and Transversalis Fascia Plane Block for Analgesia After Open Inguinal Hernia Repair
Pain, Postoperative, Inguinal Hernia Unilateral
Recruiting
Transversalis Fascia Plane Block Versus Low-Dose Intrathecal Morphine for Open Inguinal Hernia Repair
Postoperative Pain
Recruiting
Analgesic Efficacy of Quadratus Lumborum vs. Transversalis Fascia Block in Inguinal Hernia Surgery
Pain, Postoperative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing us guided Transversalis fascia plane block in people with Transversalis Fascia Plane Block, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time to first rescue analgesia (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2025.